Literatur
Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32
Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–640
Minckwitz G von, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804
Einhaltung der ethischen Richtlinien
Interessenkonflikt. D. Forstmeyer gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Forstmeyer, D. Weitere Erfolge der dualen HER2-Blockade. Onkologe 19, 1078–1079 (2013). https://doi.org/10.1007/s00761-013-2594-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-013-2594-x